Sunday 13 July 2014
Olaparib (AZD-2281) is an experimental chemotherapeutic agent, developed by KuDOS Pharmaceuticals and later by AstraZeneca, that is currently undergoing clinical trials.
It is an inhibitor of poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair.
PARP inhibitors / PARP inhibitor
FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy. Kim G, Ison G, McKee AE, Zhang H, Tang S, Gwise T, Sridhara R, Lee E, Tzou A, Philip R, Chiu HJ, Ricks TK, Palmby T, Russell AM, Ladouceur G, Pfuma E, Li H, Zhao L, Liu Q, Venugopal R, Ibrahim A, Pazdur R. Clin Cancer Res. 2015 Oct 1;21(19):4257-61. doi : 10.1158/1078-0432.CCR-15-0887 PMID: 26187614 (Free)
Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer. Tewari KS, Eskander RN, Monk BJ. Clin Cancer Res. 2015 Sep 1;21(17):3829-35. doi : 10.1158/1078-0432.CCR-15-0088 PMID: 26169965 (Free)